Drug Disposition & Biological Products

Pharmacokinetic studies are more important for therapeutic biologics . Identifying the key factors that govern absorption, distribution, metabolism,  and excretion of biologics as therapeutic agents improved the opportunities for the scientists working in drug disposition research field.

The European Union (EU) first approved a biologic in 2006, now there are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 billion to $35 billion by 2020. Generics have larger share of total global medicine spend, increasing from 27 percent ($261 billion) in 2012 to 36 percent ($421 billion) by 2017.
 

  • Drug Absorption Methods
  • Effect of pH on Drug Disposition
  • Drug Distribution
  • Drug Metabolism
  • Drug Excretion
  • Biologics and Biosimilars
  • Buffers in Biologics Manufacturing

Related Conference of Drug Disposition & Biological Products

October 16-18, 2017

12th World Pharma Congress

Budapest, Hungary
October 16-18, 2017

11th World Drug Delivery Summit

(10 Plenary Forums - 1Event)
Baltimore, Maryland, USA
October 16-17, 2017

10th International Conference and Exhibition on Biologics and Biosimilars

San Francisco, California, USA
November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Drug Disposition & Biological Products Conference Speakers

Recommended Sessions

Related Journals

Are you interested in